Scoop: Celgene targets a cure for myeloma/lymphoma with $600M EngMab buyout
Celgene has completed a deal to acquire the Swiss biotech EngMab for $600 million, adding a new BCMA-targeting multiple myeloma program to the pipeline, Endpoints News has learned. And it’s putting the new tech to work with its ongoing efforts on CAR-T and CD-3 antibodies with an eye on finding a cure for myeloma and lymphoma.
A Celgene spokesperson confirmed the deal to me in a statement Friday morning, saying that “we are acquiring Engmab for $600 million.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.